Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells (Q39616690)

13 September 2017

Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells (English)

1 reference

13 September 2017

Hao Yin

1

1 reference

13 September 2017

Yuhao Zhang

series ordinal

2

1 reference

13 September 2017

Xin Zhou

series ordinal

3

1 reference

13 September 2017

Huanzhang Zhu

series ordinal

4

1 reference

13 September 2017

23 December 2010

1 reference

Molecular Biology Reports

13 September 2017

1 reference

13 September 2017

38

1 reference

13 September 2017

8

1 reference

13 September 2017

5071-5078

1 reference

https://scigraph.springernature.com/pub.10.1007/s11033-010-0653-6

13 September 2017

0 references

cites work

Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Latency in human immunodeficiency virus type 1 infection: no easy answers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Transcriptional repression of human immunodeficiency virus type 1 by AP-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

HIV reproducibly establishes a latent infection after acute infection of T cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

The challenge of finding a cure for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Alleviation of osteoarthritis by Trichostatin A, a histone deacetylase inhibitor, in experimental osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Recruitment of SWI/SNF to the human immunodeficiency virus type 1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Trichosanthin inhibits integration of human immunodeficiency virus type 1 through depurinating the long-terminal repeats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0653-6

Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.

21 January 2018

1 reference

12 December 2020

Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation.

1 reference

12 December 2020

The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure

1 reference

12 December 2020

Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD.

1 reference

12 December 2020

Induction of chromosomally integrated HIV-1 LTR requires RBF-2 (USF/TFII-I) and Ras/MAPK signaling

1 reference

12 December 2020

10.1007/S11033-010-0653-6

Identifiers

DOI

1 reference

13 September 2017

1 reference